Seattle Genetics
1998
FOUNDED
PUBLIC
STATUS
1K-5K
EMPLOYEES
SGEN
STOCK SYMBOL
4
INVESTMENTS
$61.95
SHARE PRICE
(As of Wednesday Closing)
Description
Developer of antibody-based therapies designed to offer treatment of cancer. The company's antibody-based therapies offers advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells, enabling doctors to improve patient outcomes.
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
- 21823 - 30th Drive South East
- Bothell, WA 98021
- United States
+1 (425) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Seattle Genetics’s full profile, request a free trial.
Seattle Genetics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $48.13 - $82.76 | $9.9B | $60.94 | -$1.08 | 1.17M | 160M |
Seattle Genetics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
FY 2015
31-Dec-2015
|
|---|---|---|---|---|
| Enterprise Value | 11,798,022 | 7,249,768 | 6,877,938 | 5,532,115 |
| Revenue | 609,792 | 482,250 | 418,147 | 336,802 |
| EBITDA | (168,525) | (134,618) | (122,077) | (105,981) |
| Net Income | (162,089) | (125,530) | (140,111) | (120,486) |
| Total Assets | 1,567,845 | 877,949 | 838,396 | 895,095 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Seattle Genetics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 00000000 | 09-Mar-2018 | 000000000000000000 | 00000 | Biotechnology | 0000 0000000 00.0 |
| 0000000-00000 0000 | 01-Oct-2017 | 000000000 00000 00 | 000.00 | Buildings and Property | 0000 0000000 00.0 |
| 00000 00000 000000 | 01-Aug-2017 | 000000000000000000 | 000.00 | Laboratory Services (Healthcare) | 000000 00000 00.0 |
| UNUM Therapeutics | 11-Jun-2015 | Early Stage VC | 0000 | Biotechnology | 0000 0000000 00.0 |
Seattle Genetics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 000000000000 | 11-Jun-2015 | 00000 00000 00 | 0000 | Completed |
|
Seattle Genetics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Executive Team (14)
3 Former Executives
You’re viewing 5 of 14 executives. Get the full list »Seattle Genetics Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Felix Baker Ph.D | Baker Bros. Advisors | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 1 of 3 board members. Get the full list »